Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.89 +1.20%

+$0.15 today

Market cap
$341.49M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.11M

Average 0.09M

LYEL Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Lyell Immunopharma, Inc.NASDAQ: LYEL

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to -116500.0%

Gross margin was -116500.0% in Q1 FY2026, down 116600.0 pp from a year earlier. On a trailing-twelve-month basis it was -7422.6%, down 7522.6 pp year over year. Over 3 fiscal years it narrowed by 32052.8 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-116500.0%-116600.0 pp QoQ
Last fiscal yearDec 2025
-31952.8%-32052.8 pp YoY
LTMMar 2026
-7422.6%-7522.6 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-116600.0 pp——
1 year-32052.8 pp——
3 years-32052.8 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
-31952.8%
Year-over-year change
-32052.8pp

Gross Margin vs competitors

How LYEL compares with its peers on the latest reported figures

  • LYEL's LTM Mar 2026 gross margin of -7422.6% is the lowest of the 6 companies compared; the peer median is 52.5%.
  • Its year-over-year change of -7522.6 pp is the lowest of 4, against a peer median of +18.0 pp.
  • Over three fiscal years its change of -32052.8 pp compares with a peer median of +0.0 pp.
LYEL Competitors Peer median
Gross Margin for LYEL and competitors
Company Period LTM level YoY 3-year change
ACIUAC Immune S.A.LTM Mar 2026100.0% +0.0 pp+0.0 pp
SLNSilence Therapeutics plcLTM Mar 202666.4% —+23.7 pp
AMRNAmarin Corporation plcLTM Mar 202652.5% +18.0 pp-9.1 pp
EDITEditas Medicine, Inc.LTM Mar 20265.8% +124.1 pp+32.1 pp
GNLXGenelux CorporationLTM Mar 2026-3550.0% —-7166.3 pp
LYELLyell Immunopharma, Inc.LTM Mar 2026-7422.6% -7522.6 pp-32052.8 pp
LRMRLarimar Therapeutics, Inc.FY2025— ——
KYTXKyverna Therapeutics, Inc.FY2025— ——
ALLOAllogene Therapeutics, Inc.FY2025— ——
CABACabaletta Bio, Inc.FY2025— ——
ALDXAldeyra Therapeutics, Inc.FY2025— ——
Peer median (excluding LYEL) 52.5%+18.0 pp+0.0 pp

Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.65M84.68M130K61K36K
Cost of Revenue000011.54M
Gross Profit10.65M84.68M130K61K(11.5M)
Gross Margin100.0%100.0%100.0%100.0%-31952.8%
Research & Development138.69M159.19M182.95M171.6M158.68M
Selling, General & Admin89.06M117.31M66.98M52.04M45.14M
Operating Expenses225.43M271.74M247.14M358.82M192.27M
Depreciation & Amortization13.62M18.02M20.25M19.63M11.54M
EBITDA(236.6M)(165.1M)(214.38M)(200.64M)(262.91M)
EBITDA Margin-2221.5%-195.0%-164909.2%-328923.0%-730302.8%
Operating Income(214.78M)(187.06M)(247.01M)(358.76M)(203.77M)
Operating Margin-2016.7%-220.9%-190006.2%-588123.0%-566038.9%
Interest Income1.17M7.05M23.45M24.07M13.08M
Interest Expense00000
Other Income / Expenses(35.44M)3.94M12.38M15.76M(70.67M)
Income Before Tax(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Pre-Tax Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
Income Tax Expense00000
Net Income(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Net Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
EPS (Basic)(1.03)(0.74)(0.93)(1.31)(16.06)
EPS (Diluted)(1.03)(0.74)(0.93)(1.31)(16.06)
Weighted Avg Shares12.14M12.35M12.55M13.07M17.09M
Weighted Avg Shares (Diluted)12.14M12.35M12.55M13.07M17.09M

Lyell Immunopharma, Inc.

NASDAQ:LYEL

Intrinsic Alpha fair value

Locked

Current Price

$13.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.